All In Biotech

Drug Trial Radar · NCT07301255

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Asthma

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jan 9, 2026

Primary completion

Dec 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Enveda TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.

Conditions

  • Asthma

Interventions

  • ENV-294Drug

    ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks.

  • PlaceboDrug

    Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse EventsTime frame: From first dose through approximately 16 weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Enveda Investigative Site

    Birmingham, Alabama · Recruiting

  • Enveda Investigative Site

    Los Angeles, California · Recruiting

  • Enveda Investigative Site

    San Jose, California · Recruiting

  • Enveda Investigative Site

    West Hills, California · Recruiting

  • Enveda Investigative Site

    Colorado Springs, Colorado · Recruiting

  • Enveda Investigative Site

    Hialeah, Florida · Recruiting

  • Enveda Investigative Site

    Miami, Florida · Recruiting

  • Enveda Investigative Site

    Albany, Georgia · Recruiting

  • Enveda Investigative Site

    Maryville, Illinois · Recruiting

  • Enveda Investigative Site

    Kansas City, Kansas · Recruiting

  • Enveda Investigative Site

    Owensboro, Kentucky · Recruiting

  • Enveda Investigative Site

    Boston, Massachusetts · Recruiting

  • Enveda Investigative Site

    Southfield, Michigan · Recruiting

  • Enveda Investigative Site

    St Louis, Missouri · Recruiting

  • Enveda Investigative Site

    The Bronx, New York · Recruiting

  • Enveda Investigative Site

    Clackamas, Oregon · Recruiting

  • Enveda Investigative Site

    Medford, Oregon · Recruiting

  • Enveda Investigative Site

    North Charleston, South Carolina · Recruiting

  • Enveda Investigative Site

    McKinney, Texas · Recruiting

  • Enveda Investigative Site

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.